158 related articles for article (PubMed ID: 35662032)
21. A generic high-dose rate (192)Ir brachytherapy source for evaluation of model-based dose calculations beyond the TG-43 formalism.
Ballester F; Carlsson Tedgren Å; Granero D; Haworth A; Mourtada F; Fonseca GP; Zourari K; Papagiannis P; Rivard MJ; Siebert FA; Sloboda RS; Smith RL; Thomson RM; Verhaegen F; Vijande J; Ma Y; Beaulieu L
Med Phys; 2015 Jun; 42(6):3048-61. PubMed ID: 26127057
[TBL] [Abstract][Full Text] [Related]
22. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
23. Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy.
Wang T; Press RH; Giles M; Jani AB; Rossi P; Lei Y; Curran WJ; Patel P; Liu T; Yang X
Br J Radiol; 2019 May; 92(1097):20190089. PubMed ID: 30912959
[TBL] [Abstract][Full Text] [Related]
24. A generic TG-186 shielded applicator for commissioning model-based dose calculation algorithms for high-dose-rate
Ma Y; Vijande J; Ballester F; Tedgren ÅC; Granero D; Haworth A; Mourtada F; Fonseca GP; Zourari K; Papagiannis P; Rivard MJ; Siebert FA; Sloboda RS; Smith R; Chamberland MJP; Thomson RM; Verhaegen F; Beaulieu L
Med Phys; 2017 Nov; 44(11):5961-5976. PubMed ID: 28722180
[TBL] [Abstract][Full Text] [Related]
25. AAPM recommendations on medical physics practices for ocular plaque brachytherapy: Report of task group 221.
Thomson RM; Furutani KM; Kaulich TW; Mourtada F; Rivard MJ; Soares CG; Vanneste FM; Melhus CS
Med Phys; 2020 Jun; 47(5):e92-e124. PubMed ID: 31883269
[TBL] [Abstract][Full Text] [Related]
26. Accuracy of applicator tip reconstruction in MRI-guided interstitial 192Ir-high-dose-rate brachytherapy of liver tumors.
Wybranski C; Eberhardt B; Fischbach K; Fischbach F; Walke M; Hass P; Röhl FW; Kosiek O; Kaiser M; Pech M; Lüdemann L; Ricke J
Radiother Oncol; 2015 Apr; 115(1):72-7. PubMed ID: 25779722
[TBL] [Abstract][Full Text] [Related]
27. Interstitial high-dose-rate brachytherapy and local anesthesia for prostate cancer: a feasibility report.
Pellizzon AC
Curr Urol Rep; 2008 Jan; 9(1):45-9. PubMed ID: 18366973
[TBL] [Abstract][Full Text] [Related]
28. Experiences with a new high-dose-rate brachytherapy (HDR-BT) boost technique for T3b prostate cancer.
Rades D; Schwarz R; Todorovic M; Thurmann H; Graefen M; Walz J; Schild SE; Dunst J; Alberti W
Strahlenther Onkol; 2007 Jul; 183(7):398-402. PubMed ID: 17609874
[TBL] [Abstract][Full Text] [Related]
29. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
[TBL] [Abstract][Full Text] [Related]
30. Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT.
de Chavez R; Grogan G; Hug B; Howe K; Grigg A; Waterhouse D; Lane J; Glyde A; Brown E; Bydder S; Pryor D; Hargrave C; Charles PH; Hellyer J; Ebert MA
Med Dosim; 2022 Spring; 47(1):61-69. PubMed ID: 34551879
[TBL] [Abstract][Full Text] [Related]
31. Gantry-Based 5-Fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes From 2 Prospective Studies Comparing SABR Boost With MR Dose-Painted HDR Brachytherapy Boost.
Musunuru HB; Cheung P; Vesprini D; Liu SK; Chu W; Chung HT; Morton G; Deabreu A; Davidson M; Ravi A; Helou J; Ho L; Zhang L; Loblaw A
Int J Radiat Oncol Biol Phys; 2022 Mar; 112(3):735-743. PubMed ID: 34637882
[TBL] [Abstract][Full Text] [Related]
32. AAPM task group report 302: Surface-guided radiotherapy.
Al-Hallaq HA; Cerviño L; Gutierrez AN; Havnen-Smith A; Higgins SA; Kügele M; Padilla L; Pawlicki T; Remmes N; Smith K; Tang X; Tomé WA
Med Phys; 2022 Apr; 49(4):e82-e112. PubMed ID: 35179229
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
Makino T; Mizokami A; Namiki M
Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
[TBL] [Abstract][Full Text] [Related]
35. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer.
Nag S; Beyer D; Friedland J; Grimm P; Nath R
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):789-99. PubMed ID: 10386635
[TBL] [Abstract][Full Text] [Related]
36. A dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy.
Hermesse J; Biver S; Jansen N; Lenaerts E; De Patoul N; Vynckier S; Coucke P; Scalliet P; Nickers P
Strahlenther Onkol; 2009 Nov; 185(11):736-42. PubMed ID: 19899007
[TBL] [Abstract][Full Text] [Related]
37. HDR brachytherapy boost using MR-only workflow for intermediate- and high-risk prostate cancer: 8-year results of a pilot study.
Lakosi F; Antal G; Pall J; Farkas A; Jenei T; Nagy D; Liptak J; Sipocz I; Pytel A; Csima M; Gulyban A; Toller G
Brachytherapy; 2021; 20(3):576-583. PubMed ID: 33478906
[TBL] [Abstract][Full Text] [Related]
38. Quality assurance of HDR prostate plans: program implementation at a community hospital.
Rush JB; Thomas MD
Med Dosim; 2005; 30(4):243-8. PubMed ID: 16275567
[TBL] [Abstract][Full Text] [Related]
39. Prostate CT segmentation method based on nonrigid registration in ultrasound-guided CT-based HDR prostate brachytherapy.
Yang X; Rossi P; Ogunleye T; Marcus DM; Jani AB; Mao H; Curran WJ; Liu T
Med Phys; 2014 Nov; 41(11):111915. PubMed ID: 25370648
[TBL] [Abstract][Full Text] [Related]
40. Computed tomography versus magnetic resonance imaging in high-dose-rate prostate brachytherapy planning: The impact on patient-reported health-related quality of life.
Harris AA; Wu M; Deirmenjian JM; Shea SM; Kang H; Patel R; Fielder D; Mysz ML; Harkenrider MM; Solanki AA
Brachytherapy; 2021; 20(1):66-74. PubMed ID: 33160849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
